Share This Page
Drug Price Trends for HM MUCUS DM MAX ER
✉ Email this page to a colleague

Average Pharmacy Cost for HM MUCUS DM MAX ER
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
HM MUCUS DM MAX ER 1200-60 MG | 62011-0423-01 | 0.56382 | EACH | 2024-08-21 |
HM MUCUS DM MAX ER 1200-60 MG | 62011-0423-01 | 0.51117 | EACH | 2024-07-17 |
HM MUCUS DM MAX ER 1200-60 MG | 62011-0423-01 | 0.55176 | EACH | 2024-06-19 |
HM MUCUS DM MAX ER 1200-60 MG | 62011-0423-01 | 0.56466 | EACH | 2024-05-22 |
HM MUCUS DM MAX ER 1200-60 MG | 62011-0423-01 | 0.55836 | EACH | 2024-04-17 |
HM MUCUS DM MAX ER 1200-60 MG | 62011-0423-01 | 0.54120 | EACH | 2024-03-20 |
HM MUCUS DM MAX ER 1200-60 MG | 62011-0423-01 | 0.56027 | EACH | 2024-02-21 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for HM MUCUS DM MAX ER
Introduction to Guaifenesin and HM MUCUS DM MAX ER
Guaifenesin, an expectorant commonly used to help clear mucus and phlegm from the airways, is a key ingredient in various cough and cold medications, including HM MUCUS DM MAX ER. This drug combines guaifenesin with dextromethorphan, a cough suppressant, to provide relief from coughs and chest congestion.
Global Guaifenesin Market Overview
The global guaifenesin market is projected to reach USD 95 million by 2027, growing at a Compound Annual Growth Rate (CAGR) of approximately 3.1% from 2022 to 2027[1][3].
Market Segmentation
By Application
The cough treatment drug segment, which includes products like HM MUCUS DM MAX ER, is the fastest-growing segment in the guaifenesin market. This segment is driven by the increasing need for respiratory health management, particularly post-pandemics like COVID-19. The broader expectorant drugs market, which includes guaifenesin-based products, is valued at USD 17,648.2 million in 2024 and is projected to reach USD 38,455.4 million by 2034, growing at a CAGR of 4.3% from 2024 to 2034[1].
By Product
HM MUCUS DM MAX ER falls under the extended-release tablet category, which is one of the product segments analyzed in the guaifenesin market. Extended-release formulations are gaining popularity due to their convenience and efficacy in managing symptoms over a longer period[3].
Demand Drivers
- Growing Application in Cough Treatment: The increasing use of guaifenesin in cough treatment drugs, especially in hospitals and clinics, is a significant driver. For instance, the Indian pharmaceutical sector is expected to reach USD 65 billion by 2024 and around USD 120-130 billion by 2030, which will further boost the demand for guaifenesin[1].
- Consumer Interest in Oral Medications: Increasing consumer interest in oral medications, including expectorants, contributes to the demand. China, with its reliance on traditional Chinese medicine and high incidence of respiratory diseases, is a key market[1].
- Advancements in Hospital Infrastructure: The robust advancement in hospital infrastructure and innovation in drug delivery and processing projects will also boost the growth prospects for guaifenesin-based products[3].
Price Trends and Projections
Raw Material Costs
Fluctuations in the cost of raw materials such as glycerin and guaiacol can impact the final product price of HM MUCUS DM MAX ER. Any increase in these costs could lead to higher prices for the end product[1].
Regulatory Environment
Changes in regulatory standards related to pharmaceutical manufacturing and safety can affect production costs and subsequently prices. Stringent regulations against the use of cough suppressants may also influence pricing strategies[4].
Market Competition
The presence of substitutes and the overall competitive landscape in the expectorant drugs market can influence pricing strategies. For example, the availability of generic versions of similar drugs can drive prices down[2].
Regional Market Analysis
North America
The North American market, particularly the U.S., sees significant demand for guaifenesin due to high hospital drug expenses. According to the American Hospital Association, hospital drug expenses per adjusted discharge increased by 30.3% in 2020-21 compared to 2019[1].
Asia-Pacific
China is a key market with an anticipated CAGR of 8.1% for expectorant drugs by 2034. The country's healthcare system, which includes traditional Chinese medicine, drives the demand for expectorant herbs and medications. The Asia-Pacific region is expected to be the fastest-growing region for guaifenesin-based products, including HM MUCUS DM MAX ER[1][5].
Challenges and Opportunities
Availability of Substitutes
The global guaifenesin market faces challenges from the availability of substitute expectorants, which can impact market share and pricing. However, innovations in drug delivery and processing can enhance the efficacy and appeal of guaifenesin-based products, potentially leading to higher demand and stable or increasing prices[1][3].
Technological Advancements
Technological advancements in drug delivery and processing are expected to boost the growth prospects for guaifenesin. For instance, the FDA approval for new extended-release formulations like Mucinex DM Maximum Strength has driven market growth[4].
Pricing of HM MUCUS DM MAX ER
The pricing of HM MUCUS DM MAX ER can vary based on several factors, including the pharmacy, location, and availability of discounts.
- Extended Release Formulations: For similar extended-release formulations like Mucus Relief DM, the cost can range from $13 to $20 for a supply of 20 tablets, depending on the pharmacy and any available discounts[2].
Key Takeaways
- Fastest-Growing Segment: The cough treatment drug segment is the fastest-growing in the guaifenesin market.
- Major End-Users: Multispecialty hospitals are the largest end-users of guaifenesin.
- Global Market Growth: The global expectorant drugs market, including guaifenesin-based products, is expected to grow significantly due to increasing respiratory health concerns.
- Regional Growth: Regional markets, especially in Asia-Pacific, are driving growth due to traditional medicine practices and high incidence of respiratory diseases.
FAQs
1. What is the projected market size of the global guaifenesin market by 2027? The global guaifenesin market is forecasted to reach USD 95 million by 2027[1].
2. Which segment is the fastest-growing in the guaifenesin market? The cough treatment drug segment is the fastest-growing, expected to grow at a CAGR of around 3.7% during the forecast period[1].
3. What is the significance of the multispecialty hospital segment in the guaifenesin market? The multispecialty hospital segment held the largest market share in 2021, with over 57% of the global guaifenesin market[1].
4. How does the broader expectorant drugs market impact guaifenesin-based products? The expectorant drugs market, valued at USD 17,648.2 million in 2024, is projected to reach USD 38,455.4 million by 2034, driving demand for guaifenesin-based products like HM MUCUS DM MAX ER[1].
5. What are the key drivers of the guaifenesin market? Key drivers include growing applications in cough treatment drugs, increasing consumer interest in oral medications, and advancements in hospital infrastructure and technology[1][3].
Sources Cited
- DrugPatentWatch: Market Analysis and Financial Projection for QC MUCUS RELIEF ER[1].
- Drugs.com: Mucus Relief DM Prices, Coupons, Copay Cards & Patient Assistance[2].
- IndustryARC: Guaifenesin Market Size Report, 2022-2027[3].
- Allied Market Research: Guaifenesin Market Size, Trends | Industry Report 2021 - 2030[4].
- DrugPatentWatch: Drug prices and trends for QC MUCUS RLF MAX[5].
More… ↓